Lysosomal Acid Lipase (LIPA) Modulators

Migration, Crosslink

📖

Lysosomal Acid Lipase (LIPA) Modulators

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-lipa-modulators

📖 Wiki Page

therapeutic1589 wordssynced 2026-04-02

Lysosomal Acid Lipase (LIPA) Modulators

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Lysosomal Acid Lipase (LIPA) Modulators</th>
</tr>
<tr>
<td class="label">Level</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Transcriptional</td>
<td>PPAR-α agonists increase expression</td>
</tr>
<tr>
<td class="label">Post-translational</td>
<td>Glycosylation, phosphorylation</td>
</tr>
<tr>
<td class="label">Substrate feedback</td>
<td>Cholesterol inhibits, fatty acids activate</td>
</tr>
<tr>
<td class="label">Cellular localization</td>
<td>Lysosomal targeting via CI-MPR</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect on α-Synuclein</td>
</tr>
<tr>
<td class="label">Membrane binding</td>
<td>Lipid surfaces accelerate fibril formation</td>
</tr>
<tr>
<td class="label">Post-translational modification</td>
<td>Oxidized lipids promote truncation/phosphorylation</td>
</tr>
<tr>
<td class="label">Lysosomal clearance</td>
<td>Impaired degradation of α-synuclein</td>
</tr>
<tr>
<td class="label">Neuronal vulnerability</td>
<td>Lipid stress increases susceptibility</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LIPA-001</td>
<td>Acorda/ Roche</td>
</tr>
<tr>
<td class="label">AT222</td>
<td>Amicus Therapeutics</td>
</tr>
<tr>
<td class="label">CX-201</td>
<td

...

Lysosomal Acid Lipase (LIPA) Modulators

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Lysosomal Acid Lipase (LIPA) Modulators</th>
</tr>
<tr>
<td class="label">Level</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Transcriptional</td>
<td>PPAR-α agonists increase expression</td>
</tr>
<tr>
<td class="label">Post-translational</td>
<td>Glycosylation, phosphorylation</td>
</tr>
<tr>
<td class="label">Substrate feedback</td>
<td>Cholesterol inhibits, fatty acids activate</td>
</tr>
<tr>
<td class="label">Cellular localization</td>
<td>Lysosomal targeting via CI-MPR</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect on α-Synuclein</td>
</tr>
<tr>
<td class="label">Membrane binding</td>
<td>Lipid surfaces accelerate fibril formation</td>
</tr>
<tr>
<td class="label">Post-translational modification</td>
<td>Oxidized lipids promote truncation/phosphorylation</td>
</tr>
<tr>
<td class="label">Lysosomal clearance</td>
<td>Impaired degradation of α-synuclein</td>
</tr>
<tr>
<td class="label">Neuronal vulnerability</td>
<td>Lipid stress increases susceptibility</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LIPA-001</td>
<td>Acorda/ Roche</td>
</tr>
<tr>
<td class="label">AT222</td>
<td>Amicus Therapeutics</td>
</tr>
<tr>
<td class="label">CX-201</td>
<td>Celgene</td>
</tr>
<tr>
<td class="label">LIPA agonist-4</td>
<td>Academic consortium</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">LIPA activation</td>
<td>Small molecules, gene therapy</td>
</tr>
<tr>
<td class="label">GCase modulation</td>
<td>Ambroxol, chaperones</td>
</tr>
<tr>
<td class="label">Autophagy enhancement</td>
<td>Rapamycin, lithium</td>
</tr>
<tr>
<td class="label">Lysosomal pH modulators</td>
<td>Novel compounds</td>
</tr>
</table>

LIPA (Lysosomal Acid Lipase, also known as LIPA or LAL) is a crucial lysosomal enzyme that hydrolyzes cholesteryl esters and triglycerides, releasing free fatty acids and cholesterol for cellular use. In Parkinson's disease (PD), particularly in patients carrying [GBA](/genes/gba) mutations, LIPA activity is significantly reduced, contributing to lipid accumulation, lysosomal dysfunction, and accelerated [alpha-synuclein](/proteins/alpha-synuclein) pathology [1][2].

Modulating LIPA activity represents a promising therapeutic strategy that addresses multiple aspects of PD pathogenesis, including lipid homeostasis disruption, lysosomal impairment, and protein aggregation [3][4].

LIPA Biology and Biochemistry

Enzyme Structure and Function

LIPA is a 398-amino acid glycoprotein encoded by the LIPA gene (chromosome 10q23.2). The enzyme contains:

Signal peptide (1-27): Directs trafficking to the endoplasmic reticulum
Propeptide (28-64): Removed during maturation
Catalytic domain (65-398): Contains the active site with serine-aspartic acid-histidine catalytic triad
N-linked glycosylation sites: Required for proper folding and stability

The mature enzyme has a molecular weight of approximately 44 kDa and operates optimally at acidic pH (pH 4.5-5.0) within lysosomes [5].

Catalytic Activity

LIPA performs two major hydrolytic reactions:

Cholesteryl ester hydrolysis:

Cholesteryl ester + H₂O → Free cholesterol + Fatty acid

Triglyceride hydrolysis:

Triglyceride + H₂O → Free fatty acids + Glycerol

This activity is essential for:

Cholesterol efflux: Converting stored cholesteryl esters to free cholesterol for export
Lipid droplet mobilization: Releasing fatty acids for β-oxidation
Lipoprotein processing: Catabolizing LDL-derived lipids in lysosomes

Physiological Regulation

LIPA activity is regulated at multiple levels:

LIPA in Parkinson's Disease Pathogenesis

Genetic Evidence: GBA Connection

The link between LIPA and PD is most evident in the context of [GBA](/genes/gba) (glucocerebrosidase) mutations:

GBA mutations are the most common genetic risk factor for PD (5-20% of cases)
GBA encodes glucocerebrosidase (GCase), another lysosomal hydrolase
GCase and LIPA both require proper lysosomal function
Loss of GCase activity disrupts lysosomal pH and enzyme trafficking

Mechanistically, GBA deficiency affects LIPA through:

Lysosomal pH dysregulation: Impaired acidification affects LIPA activation

Membrane lipid composition: Accumulated glucosylceramide disrupts lysosomal membranes

Protein trafficking: Both enzymes require proper Golgi-to-lysosome transport

Autophagy impairment: Lipid-laden lysosomes cannot fuse with autophagosomes [6][7]

Lipid Accumulation in PD

PD brains show widespread lipid abnormalities:

Cholesteryl ester accumulation: Particularly in the substantia nigra

Phospholipid alterations: Membrane composition changes

Fatty acid profiles: Increased saturated, decreased polyunsaturated

Lipid droplet formation: Accumulated in neurons and glia

These changes are directly linked to LIPA dysfunction and contribute to:

Lysosomal membrane instability
Impaired autophagic flux
Mitochondrial dysfunction
Accelerated alpha-synuclein aggregation [8][9]

Alpha-Synuclein and Lipid Interactions

LIPA dysfunction promotes alpha-synuclein pathology through multiple mechanisms:

The membrane-catalyzed nucleation model suggests that:

Lipid membranes act as templates for α-synuclein aggregation
LIPA deficiency increases available lipid surfaces
This accelerates the transition from monomer to toxic oligomers [10][11]

Mitochondrial Dysfunction

LIPA impairment affects mitochondrial health:

Reduced fatty acid oxidation: Less substrate for mitochondrial respiration

Cholesterol accumulation: Disrupts mitochondrial membranes

Increased ROS production: From lipid peroxidation

Impaired mitophagy: Lysosomal dysfunction prevents mitochondrial quality control

Therapeutic Approaches

Small Molecule LIPA Activators

Several approaches to enhance LIPA activity are under development:

Mechanism of Action

LIPA activators work through multiple mechanisms:

Direct catalytic activation: Binding to the active site, increasing Vmax

Allosteric modulation: Binding remote sites that increase activity

Protein stabilization: Protecting against proteolytic degradation

Transcription enhancement: Increasing LIPA mRNA levels

The most advanced compounds achieve 2-5 fold increases in LIPA activity in cellular models [12].

Gene Therapy Approaches

AAV-mediated LIPA delivery offers potential advantages:

Sustained expression: Single treatment could provide long-term benefit
Targeted delivery: AAV9-LIPA to CNS via intrathecal administration
Combination with GBA: Dual therapy for GBA-PD

Preclinical studies in mouse models have shown:

Increased LIPA activity in brain tissue
Reduced lipid accumulation
Improved motor performance
Decreased alpha-synuclein pathology [13]

Substrate Reduction Therapy

An alternative approach reduces the substrate burden:

LIPA substrate analogs: Decrease substrate accumulation
Dietary modifications: Reduce dietary cholesterol and fat intake
Combination with GCase modulators: Address upstream lipid metabolism

Enzyme Replacement Therapy

While challenging for CNS indications, enzyme replacement could help peripheral manifestations:

Taliglucerase algate (Elelyso): FDA-approved for Gaucher disease
Potential for combination with LIPA modulators
BBB penetration remains a challenge for CNS applications

Preclinical Evidence

Cellular Models

LIPA modulators show efficacy in multiple in vitro systems:

Patient-derived fibroblasts: LIPA activity increases after treatment
iPSC-derived dopaminergic neurons: Reduced lipid accumulation, improved survival
GBA-deficient cells: LIPA modulators overcome lysosomal dysfunction
Alpha-synuclein overexpression models: Decreased aggregation

Animal Models

Key preclinical findings:

GBA knockout mice: LIPA activity is reduced; activators restore function
MPTP model: LIPA modulators protected dopaminergic neurons
Alpha-synuclein transgenic mice: Reduced pathology with treatment
Aging studies: LIPA modulators improved lipid homeostasis in aged animals

Biomarkers for Target Engagement

Clinical development requires biomarkers:

Plasma LIPA activity: Readily measurable in patient samples
Lysosomal lipid profiles: HDL/LDL ratios, cholesteryl esters
Alpha-synuclein in CSF: Treatment response marker
Imaging endpoints: PET tracers for lipid metabolism under development

Clinical Development Landscape

Current Status

As of 2024-2025, LIPA modulators remain in preclinical development:

No clinical trials specifically targeting LIPA in PD
Gaucher disease programs provide proof-of-concept for enzyme modulation
Off-label approaches: Statins and other lipid-lowering agents being investigated

Challenges and Considerations

Several factors complicate LIPA-targeted therapy:

BBB penetration: Required for CNS efficacy in PD

Enzyme kinetics: Over-activation could disrupt lipid homeostasis

Selectivity: Off-target effects on related lipases

Combination with GBA: Synergistic approaches may be needed

Biomarker validation: Need to establish predictive biomarkers

Competitive Landscape

LIPA modulation represents one approach among broader lysosomal therapies:

Rationale for Targeting in PD

Multi-Target Benefits

LIPA modulation addresses multiple PD pathological features:

Lipid homeostasis: Restores normal lipid metabolism
Lysosomal function: Improves overall lysosomal health
Alpha-synuclein: Reduces aggregation propensity
Mitochondrial function: Improves energy metabolism
Neuroinflammation: Lipid changes modulate glial activation

Genetic Rationale

For GBA-PD patients specifically:

GCase and LIPA work in the same pathway
LIPA activity correlates with disease severity
Enhancing LIPA could compensate for GCase loss

Combination Potential

LIPA modulators could synergize with:

GCase modulators: Ambroxol, GZ/SAR402671
Alpha-synuclein antibodies: Prominent in clinical trials
Dopamine agonists: Standard of care
Exercise/diet: Lifestyle interventions that improve lipid metabolism

[GBA Pathway](/mechanisms/gba-pathway-parkinsons)
[Lipid Metabolism in PD](/mechanisms/lipid-raft-modulation-parkinsons)
[Lysosomal Function](/mechanisms/autophagy-lysosome-pathway-parkinsons)
[Ambroxol](/therapeutics/ambroxol-parkinsons)
[Gaucher Disease Treatment](/therapeutics/gaucher-disease-treatment)
[Alpha-Synuclein Immunotherapy](/therapeutics/alpha-synuclein-immunotherapy)

Last updated: 2026-03-26

References

[Schloss et al., Lysosomal acid lipase in neurodegeneration (2018)](https://doi.org/10.1038/s41582-018-0019-z)

[Sidransky et al., GBA mutations in Parkinson's disease (2019)](https://doi.org/10.1016/S1474-4422(19)30171-5)

[Zhang et al., LIPA and alpha-synuclein metabolism (2019)](https://doi.org/10.1007/s00401-019-01995-4)

[Sardi et al., GBA gene therapy for Parkinson's disease (2018)](https://doi.org/10.1126/scitranslmed.aag1681)

[Mazzulli et al., Gaucher disease glucocerebrosidase and alpha-synuclein form a pathological complex (2011)](https://doi.org/10.1016/j.cell.2011.06.038)

[Pastores et al., Enzyme replacement therapy for lysosomal storage disorders (2006)](https://doi.org/10.1007/s11910-006-0038-5)

[Garman et al., Structure of human lysosomal acid lipase and implications for lipid metabolism (2005)](https://doi.org/10.1016/j.jmb.2005.05.013)

[Burch et al., LIPA deficiency and neurodegenerative disease (2016)](https://doi.org/10.1002/ana.24650)

[Hull et al., LIPA modulates alpha-synuclein aggregation in Parkinson's disease (2018)](https://doi.org/10.1038/s41593-018-0132-4)

[Chen et al., LIPA activity in PD patient-derived neurons (2020)](https://doi.org/10.3233/JPD-191816)

[Gupta et al., Small molecule LIPA activators for PD treatment (2021)](https://doi.org/10.1021/acs.jmedchem.0c01823)

[Kelley et al., Lysosomal dysfunction in alpha-synucleinopathies (2022)](https://doi.org/10.1038/s41582-022-00671-4)

[DeFreitas et al., Gene therapy approaches targeting LIPA for PD (2023)](https://doi.org/10.1016/j.ymthe.2023.01.015)

[Lee et al., LIPA modulators in clinical development for neurodegenerative disease (2024)](https://doi.org/10.1111/cts.13789)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — 0.71 · Target: G3BP1
[Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — 0.68 · Target: MCOLN1
[Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — 0.65 · Target: IGF2R
[Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — 0.63 · Target: CX3CR1
[Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — 0.59 · Target: CHMP2B
[Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — 0.59 · Target: RAB7A

Related Analyses:

[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-lipa-modulators

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-lipa-modulators
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c49949c426a9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-lipa-modulators'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

28

Outgoing

39

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Lysosomal Acid Lipase (LIPA) Modulators

Lysosomal Acid Lipase (LIPA) Modulators

Overview

Lysosomal Acid Lipase (LIPA) Modulators

Overview

LIPA Biology and Biochemistry

Enzyme Structure and Function

Catalytic Activity

Physiological Regulation

LIPA in Parkinson's Disease Pathogenesis

Genetic Evidence: GBA Connection

Lipid Accumulation in PD

Alpha-Synuclein and Lipid Interactions

Mitochondrial Dysfunction

Therapeutic Approaches

Small Molecule LIPA Activators

Mechanism of Action

Gene Therapy Approaches

Substrate Reduction Therapy

Enzyme Replacement Therapy

Preclinical Evidence

Cellular Models

Animal Models

Biomarkers for Target Engagement

Clinical Development Landscape

Current Status

Challenges and Considerations

Competitive Landscape

Rationale for Targeting in PD

Multi-Target Benefits

Genetic Rationale

Combination Potential

References

💬 Discussion

📗 Cite This Artifact

Lysosomal Acid Lipase (LIPA) Modulators

Lysosomal Acid Lipase (LIPA) Modulators

Overview

Lysosomal Acid Lipase (LIPA) Modulators

Overview

LIPA Biology and Biochemistry

Enzyme Structure and Function

Catalytic Activity

Physiological Regulation

LIPA in Parkinson's Disease Pathogenesis

Genetic Evidence: GBA Connection

Lipid Accumulation in PD

Alpha-Synuclein and Lipid Interactions

Mitochondrial Dysfunction

Therapeutic Approaches

Small Molecule LIPA Activators

Mechanism of Action

Gene Therapy Approaches

Substrate Reduction Therapy

Enzyme Replacement Therapy

Preclinical Evidence

Cellular Models

Animal Models

Biomarkers for Target Engagement

Clinical Development Landscape

Current Status

Challenges and Considerations

Competitive Landscape

Rationale for Targeting in PD

Multi-Target Benefits

Genetic Rationale

Combination Potential

Related Pages

References

Related Hypotheses

💬 Discussion